Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Subject is age 18-60 years, inclusive, and of either gender.~* Subject has a diagnosis of GNE myopathy based upon a consistent clinical course and identification of two GNE gene mutations.~* Subject must be willing to stop any treatment with ManNAc, sialic acid, intravenous immunoglobulin (IVIG), and/or other supplements containing sialic acid (e.g. St. John s wort, sialyllactose) 90 days prior to dosing and remain off such treatment for the duration of the trial.~* Subjects must have a body mass index (BMI) between 18 and 30 kg/m2, with a bodyweight of \>50 kg.~* Subjects must have 20-75% of predicted strength measured by QMA at baseline on at least one of the following: 1) ankle dorsiflexion, 2) knee flexion, 3) hip extension, 4) grip, 5) elbow flexion, shoulder abduction~  * 20-75% of predicted strength measures by OMA at baseline, or~ * If predicted muscle strength above 75%, a documented change of at least 10% per year.~* Subject has the ability to travel to the NIH Clinical Center for admissions.~* Subject has an INR less than or equal to 1.5 and must have stopped warfarin and other anticoagulants 2 weeks prior and after muscle biopsy procedures. Aspirin and clopidogrel should be stopped 3 days and 5 days before the procedure, respectively.~* Subject must be able to comply with requirements of the protocol, including blood collection, drug administration, muscle MRI/MRS, muscle biopsy and muscle strength assessments.~* If a woman of reproductive age, subject must be willing to use an effective method of contraception for the duration of the trial.~* Subject must be able to provide informed consent.~EXCLUSION CRITERIA:~* Subject had a clinical significant infection or medical illness 30 days prior to the first protocol visit.~* Subject has a psychiatric illness or neurological disease that would interfere with the ability to comply with the requirements of this protocol. This includes, but is not limited to, uncontrolled/untreated psychotic depression, bipolar disorder, schizophrenia, substance abuse or dependence, antisocial personality disorder, panic disorder, or behavioral problems, which interfere with effective communication.~* Subject has hepatic laboratory parameters (AST, ALT, GGTP) or renal laboratory parameters (creatinine, BUN) greater than 3 times the upper limit of normal.~* Subject has known adverse reactions to anesthetic or sedatives utilized for muscle biopsy.~* Subject is anemic (defined as Hematocrit \<30%) or has platelets \<100,000 or white blood cell count less than 3,000.~* Subject shows evidence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, metabolic, or gastrointestinal disease, or has a condition that requires immediate surgical intervention.~* Subject is pregnant or breastfeeding at any time during the study.~* Subject has received treatment with another investigational drug, investigational device, or approved therapy for investigational use less than 90 days prior to the first protocol visit.~* Subject has hypersensitivity to ManNAc or in the judgment of the investigator, has a condition that places the subject at increased risk for adverse effects.~* Subject has received ManNAc, sialic acid, intravenous immunoglobulin (IVIG), and/or other supplements containing sialic acid (e.g. St. John s wort, sialyllactose) less than 90 days prior to the first protocol visit.~* The presence of persistent diarrhea or malabsorption that could interfere with the subject s ability to absorb drugs or to tolerate ManNAc therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: ACTIVE_COMPARATOR): 6 subjects on Cohort A will receive oral ManNAc 3 g twice daily (6 g/day) for 7 days and, if safe, continue on 6 g twice daily (12 g/day) for the remainder of the study.
- Cohort B (Type: ACTIVE_COMPARATOR): 6 subjects on Cohort B will receive oral ManNAc 6 g twice daily (12 g/day) for the duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).